Infobird Co., Ltd
Provides Digital and Intelligent Customer Engagement Solution to
Enhance Patient Vaccination Notification Services for a Top-10
Global Pharmaceutical Company's Subsidiary
BEIJING, CHINA, June
29, 2022 -- InvestorsHub NewsWire -- Infobird Co., Ltd (NASDAQ:
IFBD) ("Infobird" or the "Company"), a leading
provider of AI-powered customer engagement solutions
in China, today announced that it has
started to provide services to a leading global pharmaceutical and
vaccine manufacturer's subsidiary with operations in China. Under
this agreement, Infobird will leverage its AI Chatbots and
experience in the healthcare industry to provide dedicated support
for the client's digital and intelligent customer engagement
initiative designed to support the client's patient notification
process for vaccines including COVID-19, HPV and various childhood
vaccines.
As one of the world's
leading professional human vaccine development and production
companies, this manufacturer has always been committed to producing
high quality and safe vaccines so that more children and families
are protected by immunization. Infobird's AI Chatbot SaaS product
can empower the vaccine manufacturer to provide customers with
professional, attentive and convenient vaccination notification
services, and therefore comprehensively improve the number of
vaccinations and promote the development of preventive
immunization. This cooperation agreement is an important step for
Infobird to, for the first time, formally provide its AI chatbot to
a client to improve patient vaccination notification.
According to Vernoster
Sullivan, the global vaccine market size increased from USD 27.5
billion in 2016 to USD 36.5 billion in 2020, accounting for 2.8% of
the total global pharmaceutical market, with a CAGR of 7.3%. With
increasing vaccine awareness among the population in low- and
middle-income countries and rising vaccine penetration, the global
vaccine market is expected to reach USD 80.9 billion and USD 136.7
billion by 2025 and 2031, with a CAGR of 17.3% and 9.1%.
In recent years, the
share of vaccine products in China's pharmaceutical market has been
on the rise. Driven by favorable government policies, technological
innovation in vaccines and increased awareness of vaccination, the
China vaccine market has increased from RMB27.1 billion in 2016 to
RMB75.3 billion in 2020, at a CAGR of 29.10%, and is expected to
reach RMB383.5 million in 2031. The market is expected to reach RMB
383.5 million by 2031, growing at a CAGR of 15.95% from 2020 to
2031. China has now become the second largest vaccine market in the
world making it essential to optimize the customer service process
through digital transformation, expand the market share of Chinese
vaccines and improve the customer experience so vaccine R&D and manufacturing
companies can better promote and support the patient benefits of
immunization,
In this cooperation,
Infobird's intelligent outbound call solution primarily includes AI
Chatbot outbound call, which will be responsible for the client's
vaccination notification, such as COVID-19 vaccine, HPV vaccine,
and various childhood vaccines. The entire process is operated by
AI without human involvement, which can help to reduce the staff's
burden while improving customer experience and helping the client
to increase the vaccination rate. At the same time, since vaccines
are one of the most effective measures to prevent and control the
COVID-19 epidemic at present, utilizing Infobird's intelligent
outbound call method is expected to help the client to notify users
of the second and third doses of COVID-19 vaccine in advance, which
is expected to largely increase the number of COVID-19 vaccinations
for the client.
The cooperation between
Infobird and the client will take place in three phases, with the
first phase focusing on intelligent outbound calling for some
hospitals/health clinics in several provinces in China. The second
and third phases will continue to expand the geographic
territory.
As a leading AI SaaS
software provider in China, Infobird is committed to making
enterprise customer engagement development more personalized and
intelligent. Infobird's solutions for the healthcare industry have
been applied in many large leading enterprises such as the
healthcare brand Taikang Health Investment, and cover multiple
business scenarios such as customer service, helping enterprises to
promote the digital transformation of customer interaction, improve
customer experience, and thus achieve cost reduction and
efficiency. In the future, the healthcare industry will continue to
be a key area of focus for Infobird, and the company will continue
to promote intelligent standard SaaS products and technologies
according to market demand, penetrate digitalization into more
healthcare service scenarios, and continue to energize the
development of the healthcare economy with intelligent
technologies.
About Infobird
Co., Ltd
Infobird, headquartered
in Beijing, China, is a software-as-a-service provider of
innovative AI-powered, or artificial intelligence enabled, customer
engagement solutions in China. For more information, visit
Infobird's website at www.Infobird.com.
Forward-Looking
Statements
This press release
contains certain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Words such as
"will, "future," "expects," "believes," and "intends," or similar
expressions, are intended to identify forward-looking statements.
Statements that are not historical facts, including statements
about the Company's beliefs and expectations, are forward-looking
statements. All forward-looking statements are inherently uncertain
as they are based on current expectations and assumptions
concerning future events, results, conditions or performance of the
Company. Readers are cautioned not to place undue reliance on these
forward-looking statements, which are only predictions and speak
only as of the date they are made. In evaluating such statements,
investors and prospective investors should review carefully various
risks and uncertainties and other matters identified in the
Company's filings with the U.S. Securities and Exchange Commission.
These risks and uncertainties could cause the Company's actual
results to differ materially from those indicated in the
forward-looking statements. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, except
as may be required by law.
Contacts
Infobird Co.,
Ltd
Yimin Wu, Chief Executive Officer
and Chairman of the Board of Directors
wuym@infobird.com
86-010-52411819
Infobird Co., Ltd
Investor Relations
TraDigital IR
Kevin McGrath
+1-646-418-7002
kevin@tradigitalir.com